[18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia

被引：27

作者：

Lee, Hyon ^{[1
]}

Seo, Seongho ^{[4
]}

Lee, Sang-Yoon ^{[4
]}

Jeong, Hye Jin ^{[5
]}

Woo, Sung-Ho ^{[5
]}

Lee, Kyoung-Min ^{[8
]}

Lee, Yeong-Bae ^{[1
]}

Park, Kee Hyung ^{[1
]}

Heo, Jae-Hyeok ^{[9
]}

Yoon, Cindy W. ^{[7
]}

Kang, Jae Myeong ^{[2
]}

Cho, Jaelim ^{[3
]}

Okamura, Nobuyuki ^{[12
]}

Furumoto, Shozo ^{[13
]}

Yanai, Kazuhiko ^{[12
,13
]}

Na, Duk L. ^{[10
,11
]}

Ido, Tatsuo ^{[5
]}

Villemagne, Victor L. ^{[14
,15
]}

Noh, Young ^{[1
,6
]}

机构：

[1] Gachon Univ, Gil Med Ctr, Dept Neurol, Incheon, South Korea

[2] Gachon Univ, Gil Med Ctr, Dept Psychiat, Incheon, South Korea

[3] Gachon Univ, Gil Med Ctr, Dept Occupat & Environm Med, Incheon, South Korea

[4] Gachon Univ, Coll Med, Dept Neurosci, Incheon, South Korea

[5] Gachon Univ, Neurosci Res Inst, Incheon, South Korea

[6] Gachon Univ, GAIHST, Dept Hlth Sci & Technol, Incheon, South Korea

[7] Inha Univ, Sch Med, Dept Neurol, Incheon, South Korea

[8] Seoul Natl Univ Hosp, Dept Neurol, Seoul, South Korea

[9] Seoul Med Ctr, Dept Neurol, Seoul, South Korea

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea

[11] Samsung Med Ctr, Neurosci Ctr, Seoul, South Korea

[12] Tohoku Med & Pharmaceut Univ, Dept Pharmacol, Sendai, Miyagi, Japan

[13] Tohoku Univ, Ctr Cyclotron & Radioisotope, Sendai, Miyagi, Japan

[14] Austin Hlth, Ctr PET, Dept Mol Imaging & Therapy, Melbourne, Vic, Australia

[15] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia

来源：

ALZHEIMER DISEASE & ASSOCIATED DISORDERS | 2018年 / 32卷 / 01期

关键词：

semantic variant primary progressive aphasia; tau; positron emission tomography; THK5351; FRONTOTEMPORAL LOBAR DEGENERATION; ALZHEIMERS-DISEASE; NEUROFIBRILLARY PATHOLOGY; DEMENTIA SEVERITY; QUANTIFICATION; TANGLES; VERSION; TOOL;

D O I：

10.1097/WAD.0000000000000216

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background:Semantic variant primary progressive aphasia (svPPA) has been associated with a variety of proteinopathies, mainly transactive response DNA-binding protein, but also with tau and -amyloid. Recently selective tau tracers for positron emission tomography (PET) have been developed to determine the presence of cerebral tau deposits in vivo. Here, we investigated the topographical distribution of THK5351 in svPPA patients.Materials and Methods:Five svPPA patients, 14 Alzheimer's disease patients, and 15 age-matched normal controls underwent [F-18]-THK5351 PET scans, magnetic resonance imaging, and detailed neuropsychological tests. [F-18]-fluorodeoxyglucose PET was obtained in 3 svPPA patients, whereas the remaining 2 underwent amyloid PET using [F-18]-flutemetamol. Tau distribution among the 3 groups was compared using regions of interest-based and voxel-based statistical analyses.Results:In svPPA patients, [F-18]-THK5351 retention was elevated in the anteroinferior and lateral temporal cortices compared with the normal controls group (left>right), and in the left inferior and temporal polar region compared with Alzheimer's disease patients. [F-18]-THK5351 retention inversely correlated with glucose metabolism, whereas regional THK retention correlated with clinical severity. [F-18]-flutemetamol scans were negative for -amyloid.Conclusions:These findings show that [F-18]-THK5351 retention may be detected in cortical regions correlating with svPPA pathology.

引用

页码：62 / 69

页数：8